Veracyte Announces Landmark Clinical Trial Results: PAM50 Biomarker Predicts Hormone Therapy Benefit in Recurrent Prostate Cancer

Reuters

2025/09/29

Veracyte Announces Landmark Clinical Trial Results: PAM50 Biomarker Predicts Hormone Therapy Benefit in Recurrent Prostate Cancer

Veracyte Inc. has announced new data from the prospective, randomized BALANCE trial (NCT03371719), indicating that the PAM50 molecular signature can predict which patients with recurrent prostate cancer may benefit from hormone therapy with apalutamide in addition to salvage radiation therapy. The PAM50 biomarker is currently available for research use on the Decipher GRID platform. Results from the BALANCE trial were presented by Dr. Daniel Spratt of University Hospitals Seidman Cancer Center, Case Western Reserve University, at the 2025 annual meeting of the American Society for Radiation Oncology (ASTRO) in San Francisco. According to the company, this marks the first prospective validation of a predictive biomarker in a randomized trial for non-metastatic prostate cancer.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Veracyte Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250928979637) on September 28, 2025, and is solely responsible for the information contained therein.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2571824837"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2571824837\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2571824837?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-29 04:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2571824837","market":"fut","top_or_hot":-1,"title":"Veracyte Announces Landmark Clinical Trial Results: PAM50 Biomarker Predicts Hormone Therapy Benefit in Recurrent Prostate Cancer","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Veracyte Announces Landmark Clinical Trial Results: PAM50 Biomarker Predicts Hormone Therapy Benefit in Recurrent Prostate Cancer\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/VCYT\">Veracyte Inc</a>. has announced new data from the prospective, randomized BALANCE trial (NCT03371719), indicating that the PAM50 molecular signature can predict which patients with recurrent prostate cancer may benefit from hormone therapy with apalutamide in addition to salvage radiation therapy. The PAM50 biomarker is currently available for research use on the Decipher GRID platform. Results from the BALANCE trial were presented by Dr. Daniel Spratt of University Hospitals Seidman Cancer Center, Case Western Reserve University, at the 2025 annual meeting of the American Society for Radiation Oncology (ASTRO) in San Francisco. According to the company, this marks the first prospective validation of a predictive biomarker in a randomized trial for non-metastatic prostate cancer.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Veracyte Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250928979637) on September 28, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Veracyte Announces Landmark Clinical Trial Results: PAM50 Biomarker Predicts Hormone Therapy Benefit in Recurrent Prostate Cancer</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVeracyte Announces Landmark Clinical Trial Results: PAM50 Biomarker Predicts Hormone Therapy Benefit in Recurrent Prostate Cancer\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-09-29 04:00</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Veracyte Announces Landmark Clinical Trial Results: PAM50 Biomarker Predicts Hormone Therapy Benefit in Recurrent Prostate Cancer\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/VCYT\">Veracyte Inc</a>. has announced new data from the prospective, randomized BALANCE trial (NCT03371719), indicating that the PAM50 molecular signature can predict which patients with recurrent prostate cancer may benefit from hormone therapy with apalutamide in addition to salvage radiation therapy. The PAM50 biomarker is currently available for research use on the Decipher GRID platform. Results from the BALANCE trial were presented by Dr. Daniel Spratt of University Hospitals Seidman Cancer Center, Case Western Reserve University, at the 2025 annual meeting of the American Society for Radiation Oncology (ASTRO) in San Francisco. According to the company, this marks the first prospective validation of a predictive biomarker in a randomized trial for non-metastatic prostate cancer.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Veracyte Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250928979637) on September 28, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"VCYT","symbol_name":"Veracyte Inc","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250928:nNDL6gfl3Y:1","article_id":"2571824837","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2571824837","pubTimestamp":1759089621,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Veracyte Announces Landmark Clinical Trial Results: PAM50 Biomarker Predicts Hormone Therapy Benefit in Recurrent Prostate Cancer. Veracyte Inc. has announced new data from the prospective, randomized BALANCE trial , indicating that the PAM50 molecular signature can predict which patients with recurrent prostate cancer may benefit from hormone therapy with apalutamide in addition to salvage radiation therapy. The PAM50 biomarker is currently available for research use on the Decipher GRID platform. Results from the BALANCE trial were presented by Dr. Daniel Spratt of University Hospitals Seidman Cancer Center, Case Western Reserve University, at the 2025 annual meeting of the American Society for Radiation Oncology  in San Francisco. According to the company, this marks the first prospective validation of a predictive biomarker in a randomized trial for non-metastatic prostate cancer.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligenc","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"VCYT":"Veracyte Inc","BK4139":"生物科技"},"translate_title":"Veracyte公布里程碑式临床试验结果：PAM50生物标志物预测复发性前列腺癌的激素治疗获益","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VCYT":0.9},"content_text":"Veracyte Announces Landmark Clinical Trial Results: PAM50 Biomarker Predicts Hormone Therapy Benefit in Recurrent Prostate Cancer\n    \n\nVeracyte Inc. has announced new data from the prospective, randomized BALANCE trial (NCT03371719), indicating that the PAM50 molecular signature can predict which patients with recurrent prostate cancer may benefit from hormone therapy with apalutamide in addition to salvage radiation therapy. The PAM50 biomarker is currently available for research use on the Decipher GRID platform. Results from the BALANCE trial were presented by Dr. Daniel Spratt of University Hospitals Seidman Cancer Center, Case Western Reserve University, at the 2025 annual meeting of the American Society for Radiation Oncology (ASTRO) in San Francisco. According to the company, this marks the first prospective validation of a predictive biomarker in a randomized trial for non-metastatic prostate cancer.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Veracyte Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250928979637) on September 28, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}